Plain-English translation of NCT06124287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's Disease research guide →This study is looking at whether a special MRI scan of the bowel can help doctors better predict which Crohn's disease patients will relapse (have their disease come back) after stopping biologic medications like Adalimumab, Infliximab, Certolizumab, Ustekinumab, Natalizumab, or Vedolizumab. Researchers will analyze MRI scans and medical information from up to 200 patients who have already stopped taking their biologic medication while in remission, and follow them for one year to see who stays well and who has a relapse. The goal is to create a tool that helps doctors figure out which patients are safe to stop the medication and which ones might need to stay on it longer.
Right now, doctors don't have a reliable way to know which Crohn's patients can safely stop their biologic medication without their disease coming back. This study aims to identify signs on MRI scans and in blood or stool tests that could predict relapse, which could help doctors and patients make better, more confident decisions about treatment.
You likely qualify if…
You likely don't qualify if…
Your participation is minimal — this is a study that uses information already collected as part of your regular care. Researchers will review your MRI scan that you had around the time you stopped your biologic medication, and they will collect information from your medical records (such as blood tests, stool tests, and colonoscopy results) and follow your health over one year to see if your disease stayed in remission or came back. All of this happens behind the scenes; you won't need to attend extra appointments or undergo additional procedures beyond your regular care.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United Kingdom
Sponsor
University College, London
Collaborators
British Society of Gastrointestinal and Abdominal Radiology (BSGAR)
Enrollment target
~150 participants
Started
February 2024
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
16 Years and older
Last updated on clinicaltrials.gov in May 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Maira Hameed
University College London Centre for Medical Imaging
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.